AusBiotech leads new Australian Innovation and Manufacturing tax initiative

7 April 2015
2019_biotech_test_vial_discovery_big

A new incentive spearheaded by AusBiotech has been launched to provide information on a new proposed tax policy measure to support Australian companies working in innovation sectors to commercialize and develop their concepts.

The Australian Innovation and Manufacturing (AIM) Incentive is led by AusBiotech and a collection of Australian organizations who manufacture and export their products globally. It includes the available information and a calculator to show how the incentive would work.

The AIM Incentive will provide an offset against the tax payable on profits derived from the innovation and manufacture in Australia of qualifying patented Australian intellectual property, with the incentive calculated on the qualifying IP profits generated by commercialization. Qualifying profit would be taxed at the lower rate of 10% with the standard corporate tax rate applied to other income.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology